AMPE

Ampio pharmaceuticals inc

1.06 USD
+0.85 (+404.76%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ampio pharmaceuticals inc stock is up 324% since 30 days ago. The next earnings date is Jun 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 14 May’s closed higher than April.

About Ampio pharmaceuticals inc

Ampio Pharmaceuticals, Inc. focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial. AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation, AP-019, an Inhaled Ampion treatment.